PCV79 Compliance With Warfarin Therapy by Australian Patients With Atrial Fibrillation  by Ortiz, M.S. et al.
PCV76
STANDARD COSTS AND RESOURCES ALLOCATION IN ATTAINMENT OF
TARGET LIPID LEVELS AMONG EXPERIENCED STATIN USERS: RESULTS FROM
THE STAR STUDY (STATINS TARGET ASSESSMENT IN REAL PRACTICE)
Degli Esposti L, Buda S, Sangiorgi D, Degli Esposti E
CliCon Srl, Ravenna, Italy
OBJECTIVES: The absolute Cardiovascular Disease (CVD) risk is a leading cause of
death. Guidelines recommend treatment with lipid-modifying drugs for patients
with an elevated CVD risk, since cholesterol target attainment allows a reduction of
events. Our aim was to analyze the economic impact (drugs and hospitalizations)
of LDL target attainment. METHODS: A multicenter, retrospective observational
study using administrative and laboratory databases (1.1 million health-assisted
individuals) was conducted. The enrolment date for a given patient was the last
date in year 2009 in which the patient reached its LDL therapeutic target, accord-
ingly to its CVD profile. Patients without statins prescriptions within the 18 months
preceding the enrolment date were excluded. RESULTS: A total of 17,243 patients
were enrolled (54.6% males, age 69,310,0). The annual standard cost for statins
and cardiovascular hospitalizations to achieve the therapeutic target, obtained
from a multivariable regression model, was €698. The standard annual require-
ments for welfare benefits, calculated on the basis of this approach, had a value of
14% lower (€2,914,807) than the current value of expenditure. This resource saving
was attributable to a reduced spending in hospital admissions, likely due to a correct
prevention. The standard requirements, however, showed a different items composi-
tion of expenditure; particularly, we observed an increase of the pharmaceutical ex-
penditure by 13% (€1,022,825) compared to the current value. 42% of patients did not
reach target (13% adherents, 29% non-adherents), 33% reached target (although non-
adherents), consuming 28% of the total expenditure, suggesting an over-consumption
of resources (27% used high dosages statins); this expenditure could be reallocated
within the non-target groups, increasing the adherence and switching to other statins
and/or dosages. CONCLUSIONS: The applicability of this approach and the cost-
saving achievement, needs the adoption of a reimbursement system that rewards
the care pathway not only in its individual parts (ie, drug treatments).
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TO UNITED STATES MEDICARE PERSPECTIVE
Blein C, Marty R, Roze S
HEVA, Lyon, France
OBJECTIVES: To calculate US-hospital specific DRGs payments for in-patient stays
with a primary diagnosis of stroke and assess its variability according to Medicare
inpatient prospective payment system (IPPS). METHODS: The ICD 9-CM diagnosis
codes related to stroke were selected. The coding rules and algorithms of the Medi-
care severity DRG Grouper (version V29) were analyzed to identify the distinct
stroke related Diagnosis Related Groups (DRG) depending on co-morbidities and
concomitant diagnosis. According to IPPS rules, inpatient hospital services are paid
at a predetermined rate. This latter is calculated by multiplying a DRG-relative
weight with operating and capital base payments rates. These rates are adjusted on
several hospital features such as geographical area, share of low-income patients
served, and involvement in medical education. These hospital specific DRG base
payments were implemented for each Medicare provider listed in the Federal reg-
ister, based on their information found in the 2012 PPS Impact files. Weighted
average tariffs across DRG, based on discharges rates reported in the Health care
Cost and Utilization Project (HCUP) statistics were generated and the variability of
DRG payments was also assessed through descriptive statistics. RESULTS: Distinct
DRGs are assigned during inpatient stay for stroke and their average payments to
Medicare providers ranging from $4,288 to $18,296. Overall weighted mean (median)
payments for stroke were $7,193 ($6,728) across all DRGs and Medicare providers.
DRG-tariffs distributions by region as well as other hospital characteristics (size, urban
versus rural location, teaching status) highlighted the disparities related to each of
these factors and their relative impact. These findings were compared with HCUP
aggregated statistics related to costs and hospital charges. CONCLUSIONS: Calculat-
ing hospital specific DRGs according to the US-Medicare prospective payment sys-
tem enable to get reliable cost inputs for health-economic models and relevant for
adaptation to US-local settings (regional or even hospital based).
CARDIOVASCULAR DISORDERS - Patient-Reported Outcomes & Patient
Preference Studies
PCV79
COMPLIANCE WITH WARFARIN THERAPY BY AUSTRALIAN PATIENTS WITH
ATRIAL FIBRILLATION
Ortiz MS1, Calcino G2, Germanos P3
1University of NSW, Darlinghurst, NSW, Australia, 2HI Connections, Woden, ACT, Australia,
3Boehringer Ingelheim Pty Limited, North Ryde, NSW, Australia
OBJECTIVES: To study warfarin compliance by Australian patients with Atrial Fi-
brillation (AF). METHODS: Longitudinal assessment of Pharmaceutical Benefit
Scheme (PBS) claim records provided by Medicare Australia. We analysed a 10%
random sample of all Australian long-term health concession card holders who
had taken an anti-arrhythmic medication for AF prior to a new initiation of warfa-
rin (time window October 2006 to September 2007), and for whom warfarin had not
been dispensed in the 12 months prior to the initiation. Regimen complexity was
assessed using the number of strengths of warfarin taken in a 90-day period. Treat-
ment compliance was assessed using: the proportion failing to fill a second pre-
scription; median persistence time with medication: long term persistence at 30
months. Treatment cessation was defined as 6 months without a warfarin
prescription. RESULTS: The PBS Claims database yielded information on 1,108 con-
cessional AF patients newly initiated on warfarin. These AF patients were initiated
on 2.4 different strengths of warfarin in the first 3 months and the regimen com-
plexity was 2.0 strengths 12 months later. Australian PBS claims data showed that
13% stopped warfarin after the first script. Median persistence to warfarin was 22
months, while long term persistence (30 months) was around 42%. Decreasing the
cessation criteria from 6 to 3 months revealed large treatment gaps in 16% of
warfarin patients at 2 years. CONCLUSIONS: There is a significant problem with
complex dosing regimens and poor persistence in AF patients taking warfarin.
Warfarin regimens tend to be complex with AF patients averaging 2 or more
strengths of warfarin. Not only do the majority of AF patients stop warfarin within
2 years, a further one in six had large treatment gaps. If AF patients fail to take their
anticoagulation therapy regularly, then this will substantially increase the risk of
adverse outcomes including stroke.
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OBJECTIVES: Antihypertensive single-pill combination (SPC) therapy is known to
be associated with better compliance and persistence compared to free-drug com-
binations (FC). However, due to differences in blood pressure, occurrence of hyper-
tension-related diseases, diet, and lifestyle, applying the existing results from a
Western population to a Korean population may not be acceptable. In this study,
we compared the compliance and persistence of SPC versus FC using the 2009 data
of the Health Insurance Review Agency National Patient Sample. METHODS:
Among a total of 65,477,122 prescription claims, patients who were prescribed at
least one SPC or FC in 2009, were more than 40 years old and had no history of
hospitalization, surgery, or cancer numbered 9,822 and 7,494, respectively. Com-
pliance was measured using the proportion of days covered (PDC) and calculated as
the proportion of days a patient took the index drug within the 12-month follow-up
period in 2009. Persistence with therapy was measured as the number of days from
the index date to the therapy discontinuation date, which was defined as a gap in
therapy of 30 or more days. RESULTS: The overall average PDC was 0.58 for SPC and
0.59 for FC, which was not significantly different. However, compliance varied by
comorbidity status: patients who prescribed SPC showed greater PDC than those
who were prescribed FC. Notably, among patients with dyslipidemia, diabetes, and
chronic heart disease, compliance was significantly higher for SPC than for FC: 0.64
vs. 0.61 for dyslipidemia (p0.0159), 0.63 vs. 0.60 for diabetes (p0.0062), and 0.69
vs. 0.66 for chronic heart disease (p0.0441). However, persistence was not signif-
icantly different in either the overall cohort or the cohort stratified by comorbidity.
CONCLUSIONS: Our study suggests that use of SPC in hypertensive patients with
comorbidities may provide clinical benefits by improving better compliance com-
pared with patients taking FC.
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OBJECTIVES: Premature discontinuation of antiplatelet therapy after percutane-
ous coronary intervention (PCI) is a main predictor of late stent thrombosis which
can lead to serious consequences such as death and acute myocardial infarction.
We aim to assess the impact of patients’ awareness of consequences of non-com-
pliance on self-reported adherence with antiplatelet therapy after PCI. METHODS:
We retrospectively analyzed 393 patients who underwent PCI with stent implan-
tation from the Care For Your Heart database in Hong Kong. Patients were asked
about their awareness of the risk of adverse cardiac events or death from non-
compliance with anti-platelet therapy after PCI. Patients who were non-compliant
(defined as self-reported missing more than 1 tablet per month) were compared to
those who were compliant. RESULTS: Of the 393 patients, 35.6% (n140) were
unaware that non-compliance with anti-platelet therapy was associated with any
risk, 50.9% (n235) was aware of risk of adverse cardiac events or death, and 5.9%
(n23) were considered non-compliant with prescribed antiplatelet therapy after
PCI. Non-compliant patients were predominantly male (91.3%) with an average age
of 67.00.9 years, of whom 43.5% were not aware that non-compliance was asso-
ciated with any risk compared to 35.9% (p0.03) of compliant patients. Patients
who were aware of the cardiac risks of non-compliance were more likely to adhere
to their anti-platelet regimen (48.2% vs. 28.1%; p0.03). More patients received their
information on cardiovascular health from health talks (60.3%) and printed media
(51.1%) than from their cardiologists (33.0%). CONCLUSIONS: Increased awareness
of the dire consequences of non-compliance with anti-platelet therapy is needed
among patients undergoing PCI. Health care providers are encouraged to better
educate patients to optimize adherence to medication.
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